TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Best Corrected Visual Acuity (BCVA) with Manifest Refraction (MR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-treatment PEFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary Hypertension (PH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Valvular Involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Parent Emotion Socialization Strategies
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: AUCo-∞
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiomic accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of clinical assessments
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Diagnostic rate of biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of trigger points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of unsolicited adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse reactions/events related to blood chemistry, blood routine, blood coagulation function and urinalysis indicators
Endpoint domain: Adverse events/effects
Primary endpoint: Homosystein test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in number of dyads in attendance each week
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinical outcomes of patients with hematologic malignancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and duration of Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency and duration of Treatment-related Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with venous recanalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Scores on the Fagerström Test for Nicotine Dependence (FTND)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in carbon monoxide (CO) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Salivary Cotinine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of serious bleeding episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Number of episodes of thrombotic events including thrombotic microangiopathy (TMA)
Endpoint domain: Adverse events/effects
Primary endpoint: Target Area Hair Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of daily urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Concentration of creatinine in daily urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Assessment of positive and negative symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peer aggression expulsions
Endpoint domain: Adverse events/effects
Primary endpoint: Chronic absenteeism
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Assessing pain with Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessing anxiety level with the Visual Analog Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Evaluating patient satisfaction with the Satisfaction Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intra-rater correlation coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acetabular cup position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acetabular cup loosening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of heterotopic ossification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with tumor response assessed by iRECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants with tumor response assessed by RECIST v1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: daily energy and protein intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: immunoglobulin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ex vivo vascular relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ubiquitin C-terminal hydrolase L1 (UCHL1) plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutrophil gelatinase associated lipocalin (NGAL) urine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in absorbed dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline-adjusted geometric mean ratio for plasma folate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fundus photo changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Sensitivity and specificity of sulcal tuberculomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of imaging findings with clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tenofovir (TFV) blood concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of pocket closures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in HDRS score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Locally recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Toxicity effect
Endpoint domain: Adverse events/effects
Primary endpoint: No Major Adverse Events (MAE) occurrence within 30 days after surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment success at 12 months after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Immediate surgical success rate of the Endovascular Needle System
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Adverse events related to implantation
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events related to the device and its function
Endpoint domain: Adverse events/effects
Primary endpoint: change in full mouth bleeding score (ΔFMBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diastolic Blood Pressure Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Persistent Post-Surgical Pain (PPSP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk for Subthreshold or Threshold Manic Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Subthreshold or Threshold Manic Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Affective lability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dosing Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated total blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of Post Procedure Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Units of Vaccine Dispensed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Inguinal LN size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Axillary LN size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Timely delivery of appropriate analgesic
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain levels VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurotoxicity assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Salivary melatonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: pocket depth (PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytokines and endorphins rates variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Covid infection rate
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of severe outcome
Endpoint domain: Mortality/survival
Primary endpoint: Rate of PDMP Engagement
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Volume of Potentially Guideline-discordant Opioid Prescribing
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative 28-day Pediatric Logistic Organ Dysfunction (PELOD)-2 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of symptomatic thromboembolic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Impact on Sodium test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Impact on Potassium test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Impact on Chlorure test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Impact on Bicarbonate test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Impact on Protein test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Impact on Calcium test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Glucose metabolism disorders per exposure period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Neoplasm per exposure period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Food Security Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Asthma Symptoms Control (GINA Assessment of Asthma Control)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound area measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound depth measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical function of upper limb strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical function of lower limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical function of dynamic balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen therapy period
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Addiction Severity Index (ASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neural Circuitry measured by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnosis of subclinical hypothyroidism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Retention rate from baseline to end of intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Acceptability of the study procedures assessed using a set of self-report items
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cognitive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of patients presenting Y chromosome material
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of spinal curvature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number/Rate of Words Learned
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sustained Attention to Response Task (SART) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in score on Tower Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Difficulties in Emotion Regulation Scale (DERS) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Clinician Administered PTSD Scale (CAPS) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Composite measure of care quality
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Crude Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Rash scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Bile duct patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion recommended genetic testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Recall rates of personal genomic results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with histopathological diagnosis of grade 2 cervical intraepithelial neoplasia (CIN) or worse (CIN2+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants with histopathological diagnosis of grade 3 cervical intraepithelial neoplasia (CIN) or worse (CIN3+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change of Motor Function Measure (MFM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endurance shuttle test - fatigability part
Endpoint domain: Physiological/clinical
Endpoint subdomain: Fatigue
Primary endpoint: Pre-term labour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Relapse at 3 months
Endpoint domain: Mortality/survival
Primary endpoint: Relapse at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of surgical wound infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinical complete response to SBRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the plasma concentration-time curve from 0 to 24 hours (AUC 0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on Iowa Gambling Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on Progressive Ratio Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores on Probabilistic Learning Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Access-site complication
Endpoint domain: Adverse events/effects
Primary endpoint: postoperative rescue pethidine consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Tongue protrusion peak pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tongue protrusion endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day mortality in proven AAS
Endpoint domain: Mortality/survival
Primary endpoint: Mean cumulative opioid consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: intracerebral Progression-Free-Survival (iPFS)
Endpoint domain: Mortality/survival
Primary endpoint: intracerebral Objective Response Rate (iORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Postoperative pain score: resting and dynamic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of quaternary ammonium sensitization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pressure Injury Skill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eastern Cooperative Oncology Group Performance Status (ECOGPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of LLL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of transition from stage 0-1 LLL to stage 2-3 LLL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diaphragmatic muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with no evidence of residual or local recurrent neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction of temporomandibular pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days spent at hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Intervention-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Fludarabine uptake in tumoral lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Fludarabine uptake in normal tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Perceived treatment added value
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of bronchial inflammatory cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Composition of the biliary microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI defined tumour volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cumulative rate of disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Performance evaluation of the LumiraDx SARS-CoV-2 Ag Ultra
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in liver disease severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque index change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved Social skills
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Improved Social Communication Skills
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Number of sore throat episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QOL measured as postoperative TOI-14 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Summarized postoperative pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of ketamine-assisted group psychotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Neurophysiological measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mood measures
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: bladder-intact overall survival
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of nonsuicidal self-injurous behavior
Endpoint domain: Adverse events/effects
Primary endpoint: Behavioural changes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Occurrence of any alloimmune event
Endpoint domain: Adverse events/effects
Primary endpoint: Renal function measured as the difference in eGFRCKD-EPI at 24-months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Probabilistic Selection Task (PST) performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phantom limb pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of substance abuse disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binocular photopic best-corrected distance visual acuity (BCDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scope performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Urine cannabinoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Blood cannabinoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of the actual motor competence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the physical activity level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes